Ad
related to: human gene therapy impact factor- Products & Solutions
Find the best products, solutions,
and services for your workflow.
- Resources Hub
Discover cell & gene therapy blogs,
eBooks, webinars and more.
- Products & Solutions
Search results
Results From The WOW.Com Content Network
Current Gene Therapy is a ... and ex vivo gene therapies, animal models, and human therapeutic applications. ... the 2022-2023 journal impact factor is 4.676 and the ...
Human Genetics is a peer-reviewed medical journal covering all aspects of human genetics, including legal and social issues. It was established in 1964 by Arno Motulsky and Friedrich Vogel as the German-language Humangenetik , obtaining its current title in 1976. [ 1 ]
This is one of the first studies of a CRISPR-based in vivo human gene editing therapy, where the editing takes place inside the human body. [266] The first injection of the CRISPR-Cas System was confirmed in March 2020. [267] Exagamglogene autotemcel, a CRISPR-based human gene editing therapy, was used for sickle cell and thalassemia in ...
npj series. The Nature Partner Journals series, abbreviated npj, is a series of online-only, open access, journals.It was launched in April 2014 with three journals: npj Primary Care Respiratory Medicine, npj Biofilms and Microbiomes, and npj Schizophrenia.
Gene is a peer-reviewed scientific journal in genetics and molecular biology, focusing on the cloning, structure, function, as well as the biomedical and biotechnological importance of genes. The scope of the journal includes all biological organisms including viruses, prokaryotes, and eukaryotes.
The Journal of Gene Medicine is a monthly peer-reviewed medical journal covering gene therapy and other uses of genetic technologies for medical purposes. It was established in 1999 and is published by John Wiley & Sons. The editors-in-chief is Gening Jiang (Tongji University).
At the University of Utah, scientists used a new gene therapy that reversed heart failure in animals. ... and the team plans to start human clinical trials in the fall of 2025, Hong said.
With the discovery of various types of immune-related disorders, there is a need for diversification in prevention and treatment. Developments in the field of gene therapy are being studied to be included in the scope of this treatment, but of course more research is needed to increase the positive results and minimize the negative effects of gene therapy applications. [27]
Ad
related to: human gene therapy impact factor